Guard Therapeutics International AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was SEK 23.34 million compared to SEK 32.37 million a year ago. Basic loss per share from continuing operations was SEK 2.5 compared to SEK 4.5 a year ago.
For the nine months, net loss was SEK 96.23 million compared to SEK 72.35 million a year ago. Basic loss per share from continuing operations was SEK 9.5 compared to SEK 10.5 a year ago.